Clinical characterisation of super-responders and super-non-responders in psoriasis patients treated with interleukin-17 inhibitors: A real-world study.

Background In psoriasis patients treated with biologics, some achieve an ideal response to biologics and remain clear of lesions for several months, even years (super-responders-SRs), whereas others repeatedly fail to respond (super-non-responders-SNRs) to the biologic. Objective To investigate the clinical characteristics of SRs and SNRs in psoriasis patients treated with biologic interleukin-17 inhibitors. Methods Chronic plaque psoriasis or psoriasis vulgaris patients who received IL-17i treatment for more than 6 months were included. Results In total, 664 patients were included, with 120 (18.63%) categorised as SRs and 82 (12.73%) as SNRs. Compared to SNRs, SRs were mostly female, had lower body weight and BMI, and were less likely to have received previous systemic treatment. Lower weight and BMI and the absence of previous treatment may serve as predictors of SRs. Compared to controls, the SNRs had higher body weight and BMI, longer disease duration, were more likely to have received previous systemic treatment, and had a greater number of comorbidities. Higher BMI, longer disease duration, the presence of previous treatment, and abnormal C-reactive protein (CRP) value serve as predictors of SNRs. Limitations Single-centre study has a relatively small size. Conclusion Lower BMI and the absence of previous treatment may serve as predictors of SRs. In contrast, higher BMI, longer disease duration, the presence of previous treatment, and abnormal CRP value may serve as predictors of SNRs.